Mar 27, 2019
Blueprint Medicines Announces Accelerated Regulatory Submission Plans and Recent Clinical Progress
Mar 21, 2019
CStone receives approval in China to initiate Phase 1 clinical trial for RET inhibitor BLU-667 (CS3009)
Mar 05, 2019
Blueprint Medicines to Present at 39th Annual Cowen & Co. Health Care Conference
Feb 19, 2019
Blueprint Medicines to Report Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019
Feb 07, 2019
Blueprint Medicines to Present at Upcoming Investor Conferences in February
Jan 04, 2019
Blueprint Medicines Announces "2020 Blueprint" Global Business Strategy and Outlines Key Corporate Goals
Dec 02, 2018
Blueprint Medicines Announces Updated Results from Ongoing EXPLORER Clinical Trial of Avapritinib Demonstrating Broad Clinical Activity and Significant Symptom Reductions in Patients with Systemic Mastocytosis
Sep 26, 2018
Blueprint Medicines Announces Proof-of-Concept Data Showing Combination of BLU-667 and Osimertinib Overcame Treatment Resistance in Two Patients with EGFR-Mutant, Non-Small Cell Lung Cancer and an Acquired RET Fusion
Sep 24, 2018
Blueprint Medicines Showcases Broad Portfolio of Highly Selective Investigational Kinase Medicines with Presentations at Upcoming Medical Meetings
Aug 01, 2018
Blueprint Medicines to Present at Upcoming Investor Conferences in August
Aug 01, 2018
Blueprint Medicines Reports Second Quarter 2018 Financial Results
Jun 21, 2018
Blueprint Medicines Initiates VOYAGER Phase 3 Clinical Trial of Avapritinib in Patients with Advanced Gastrointestinal Stromal Tumors
May 31, 2018
Blueprint Medicines to Present at Upcoming Investor Conferences in June
May 17, 2018
Blueprint Medicines Announces Data Presentations at Upcoming ASCO and EHA Meetings Supporting Plans for Rapid Development of Avapritinib in Patients with Gastrointestinal Stromal Tumors and Systemic Mastocytosis
Apr 15, 2018
Blueprint Medicines Publication in Cancer Discovery Highlights Preclinical and Clinical Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667
Apr 15, 2018
Blueprint Medicines Announces Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667 from Phase 1 ARROW Clinical Trial in Patients with RET-Altered Solid Tumors
Feb 14, 2018
Blueprint Medicines to Report Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 21, 2018
Dec 11, 2017
Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock
Nov 10, 2017
Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors Showing Strengthened Clinical Activity across Spectrum of KIT and PDGFRa Genotypes
Nov 08, 2017
Blueprint Medicines to Present at Jefferies Global Healthcare Conference